Table 1.

Clinical characteristics of MS patients at baseline.

RR-MS (76)
Age, years (mean, SD)	34.6 ± 10.3
Sex, F/M (N, %)	59/17 (77.6)
Disease duration, months (median, IQR)	3.6 (1.2–19.3)
Radiological activity (1 = yes, 0 = no) (N/tot (%))	37/74 (50)*
EDSS (median, IQR)	1.5 (1–2)
MSSS (median, IQR)	3.9 (2.9–6.5)
LCVA at 2.5% (median, IQR)	43 (38–45)
LCVA at 1.25% (median, IQR)	37 (32–42)
CSF IL-10 (pg/mL) (mean, SD)	2.3 ± 1.8
DMT (0 = platform, 1 = high efficacy) (N, %)	52/24 (68.4)

SD, standard deviation; N, number; IQR, interquartile range; EDSS, Expanded Disability Status Scale; MSSS, Multiple Sclerosis Severity Scale; LCVA, low-contrast visual acuity; CSF, cerebrospinal fluid; DMT, disease-modifying therapies; platform therapies: interferon beta-1a 30 mcg = 1 patient; interferon beta-1a 22 mcg = 4 patients; interferon beta-1a 44 mcg = 1 patient; peginterferon beta-1a = 3 patients; teriflunomide = 3 patients; glatiramer acetate = 11 patients; dimethyl fumarate = 29 patients; total 52; high-efficacy therapies (ocrelizumab = 2 patients; cladribine = 5 patients; fingolimod = 10 patients; natalizumab = 6 patients; rituximab = 1 patient; total 24). ^*Missing data for 2 patients.